Skip to main content

Next-Generation Saponin Adjuvants and Therapeutics

Q-VANT Biosciences contributes to the efficient development and production of effective vaccines through our unique vaccine adjuvant capabilities.

Target Product Profile

Research the most appropriate saponin adjuvant for a given vaccine considering the specifics of the disease, the antigen and co-adjuvants.

Reduce the time of vaccine development

Q-VANT presents new possibilities for the research and development of saponin adjuvants.

Regulatory

Make easier to obtain authorization for clinical trials and marketing approval from a standardized regulatory dossier and prepared audit complying with GMP global and local requirements.

Business Continuity

Q-SAP™ proprietary technology enables Q-VANT to obtain adjuvant products from a wide range of quillaja-based plant materials, emancipating from sole bark, which can increase production volumes by as much as 1,000 times.

Sustainability

Meet the sustainability goal for the adjuvant by reducing the footprint.

News

Q-VANT manufacturing facility is operational

Q-VANT new state-of-the-art manufacturing facility is officially ready to start production! This cutting-edge site leverages our…
Logo Tulane University
News

Q-Vant Collaborates with Tulane University to Develop a Promising New Oral Vaccine Adjuvant

Q-Vant Biosciences Inc., a biosciences company specialized in manufacturing and formulating open-access saponin-based adjuvants from…
Logo Q-VANT BIOSCIENCES press release social
Press

Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants

SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment…
Quillaja leaves in a plantation
News

Q-VANT and In Vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass

Enhances Q-VANT’s 100% sustainable supply for next-generation saponin adjuvants   Boston, MA – March 8,…